万维提示：
1、投稿方式：在线投稿。
2、期刊网址：http://www.jhltonline.org/
https://www.journals.elsevier.com/the-journal-of-heart-and-lung-transplantation
3、投稿网址：
https://www.editorialmanager.com/JHLT/default.aspx
4、官网邮箱：jhlteditor@ishlt.org（编辑部）
heartandlung@stellarmed.com（总编）
5、期刊刊期：月刊，一年出版12期。
2021年7月15日星期四
投稿须知【官网信息】
The Journal of Heart and Lung Transplantation
Guide for Authors
JHLT Operating Procedures, Policies and Information for Authors
JHLT websites:
https://www.jhltonline.org or https://www.editorialmanager.com/JHLT/default.aspx
AudioSlide Presentation on JHLT Editorial Workflow:Presented by Dr. Daniel Goldstein, MD
Aims and scope
The Journal of Heart and Lung Transplantation, the official publication of the International Society for Heart and Lung Transplantation, brings readers cutting-edge clinical practice, basic and translational science in the fields of cardio-pulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease, pulmonary vascular disease (pulmonary arterial hypertension and CTEPH), extracorporeal support of donor organs, and cell replacement therapy.
Editorial policies
Statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the Editor(s)or publisher, and the Editor(s) and publisher disclaim any responsibility or liability for such material. Neither the Editor(s) nor the publisher guarantees, warrants, or endorses any product or service advertised in this publication. Neither do they guarantee any claim made by the manufacturer of such product or service.
Editorial Office Contact
Any question may be directed to our office by e-mail to jhlteditor@ishlt.org or heartandlung@stellarmed.com (Mr. David Newcombe, JHLT Managing Editor). In general, an email receives a response within 72 hours. If there is an urgent issue that requires the editor's attention or intervention, it is usually attended to immediately. The journal website can be accessed at https://www.jhltonline.org.
Please do not contact the Editor-in-Chief via direct personal email. These emails will be ignored.
Manuscript submission
The Journal of Heart and Lung Transplantation will accept only online submissions of original manuscripts through the Editorial Manager system at https://www.editorialmanager.com/JHLT/default.aspx. Manuscripts submitted through this online system can easily be tracked by the authors, editors, and reviewers through final disposition. The corresponding author involved with a specific manuscript will receive automatic e-mail notification as the manuscript proceeds through the system. Click the 'Register' link on the toolbar at the top left to input author demographics and set up an account. After registration is complete, a notice will be sent via email indicating a user ID and password. Use this information to log in as an author by choosing the 'Login' link on the toolbar and select 'Submit New Manuscript.' Follow the prompts to complete the submission according to the specifications below. Further questions may be directed to the editorial office by e-mail to jhlteditor@ishlt.org or directly to the Managing Editor, David Newcombe (heartandlung@stellarmed.com). The user ID and password can be changed at any time.
Duplicate/Prior/Overlapping Publication or Submission
Manuscripts are accepted for review with the stipulation that they are submitted solely to JHLT. Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see https://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder. Authors should disclose prior publication as an abstract or an electronic preprint in the Cover Letter.
Submission Checklist
Please submit your materials as 6 separate files organized as follows and in accordance with following the guidelines below.
Cover letter of submission, to include author agreement as described below
ICMJE Disclosure form for each listed author (combined into one file)
Manuscript (double spaced, combined into one file):
Title page
Title of article
Full name(s), academic degrees, and affiliations of authors, including each author's ORCID#
Name, email address, and any relevant social media pages (i.e. Twitter handle, Facebook page, Mendeley account page, etc.) of corresponding author
Reprint and corresponding author byline
Manuscript file (double spaced), to include:
Introduction
Abstract
Material and Methods (see below), to include:
Statement of IRB/Ethics board approval
Statement of compliance with the ISHLT Ethics statement
Statement of humane animal care
Statement of informed consent
Discussion
Financial conflict of interest statement (to be included as a separate section after the Discussion and before the references)
Author contributions
Acknowledgments
Tables
Figures with legends on the same page
References
Written releases from all persons/patients whose information or likeness is represented or makes them identifiable
Permissions to reproduce material published elsewhere
Supplementary Appendix Material (if needed)
Manuscript Categories
1. For Original Science papers we review them in Clinical, Translational or Basic categories. A 250-word limit for the structured abstract and a 3000-word limit for the main text and (excluding tables, figures, and references) are allowed. We will allow an unlimited supplementary file which is designed to be made available in a PDF form and can enhance the availability of more detailed information. The supplementary should be provided as a word document or PDF and must be structured - see below for details. The articles should, in general, average 8 journal pages with no more than a total of 8 figures/tables and 40-50 references.
2. Innovation articles are accepted rarely and reserved typically for major articles that have the potential to substantially advance clinical practice or advance research. Such papers should be no more than 1500 words. The entire double-spaced, typewritten manuscript, including tables, figures, and references should be five to seven pages, and the abstract is not required to be structured and should be no more than four-five sentences.
3. Brief Communication is a unique category that is designed to publish exceptionally novel preliminary information with a high potential to change paradigms and to open new avenues of investigation. Brief Communications must contain substantive information concerning experimental or clinical studies, accompanied by a brief reference list (of no more than ten references) and three display items (Tables/Figures) and no more than 1000 words (not including 150 words for the unstructured abstract). No other subsections are permitted. Supplementary data files are permitted but anything described in such contexts must have a relevant tag in the main paper.
4. Case Anecdotes (which are designed to succinctly describe a novel clinical or surgical direction) and Comments and Opinions (which could represent a reaction to a published article or could be unrelated) should be no more than 500 words (in total main text). Authors are limited to 5 references for the Case Anecdotes, Comments and Opinion category. This communication is retained and indexed in the Cumulated Index Medicus.
5. State-of-the-Art reviews (2500 words) and Perspective pieces (1500 words) are entertained for publication in the journal. The editorial process would be greatly enhanced if prospective authors would contact the Editors for questions regarding such submissions. We shall be glad to provide direction on whether the journal would be interested in reviewing your work or if a similar line of work has already been processed or commissioned by the Editorial Office. Typically, a Perspective piece can be a discussion or debate on any ongoing clinical or scholarly issue in the field or a look into the future. Please note that your experience and scholarly standing will be paramount in our review process of these areas of work.
Study Requirements
1. For observational studies, we recommend using the STROBE criteria which are available at https://www.strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_combined.pdf
2. A review article must ideally follow the guidelines for a systematic review and meta analyses must be properly coordinated. We recommend reviewing the following guidelines for constructing such articles (http://www.ccace.ed.ac.uk/research/software-resources/systematic-reviews-and-meta-analyses).
3. A Clinical Trial (any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome) must be registered online before the start of patient enrollment. Trials in which the primary goal is to determine pharmacokinetics may be exempt. A list of acceptable registries may be found at http://www.icmje.org. You must indicate the trial registry and its access mechanism at the time of submission. In general, we advise that a list of the investigators, trial protocol, detailed inclusion and inclusion criteria and methodological information be also provided in the supplementary files.
Cover Letter/Author Agreement
The authors must include a cover letter with the manuscript submission that indicates the manuscript has not been published previously and that it is not under consideration for publication elsewhere. It should be stated that all authors agree with the content of the manuscript. The cover letter should concisely summarize the findings of the study and the importance to the field.
Informed consent
Reports describing data obtained from research conducted in human subjects must contain a statement in the Methods section indicating approval by the institutional review board or Ethics board and affirm that informed consent was obtained as required by the study authorizing entity. In some instances we may ask to see the approval certificates.
All submissions to the journal must attest their strict compliance with the ISHLT ethics statement (https://ishlt.org/ishlt/media/ISHLT/Content%20Documents/ISHLT_Statement_on_Transplant_Ethics_19-Oct-2014.pdf). In addition, for specific submissions from countries where it is known that transplants may be performed in violation of these guidelines (e.g. transplants involving executed prisoners), a specific statement to this regard is required. The above statements are required to be made within the Methods section.
Authors should remove information from photographs and manuscripts that might identify a patient. Where this is impossible, submissions must be accompanied by a written release from the patient (or any other person whose likeness is represented).
Manuscripts that do not comply with the requirements regarding informed consent will be returned during the processing phase by the Editorial Office.
Humane animal care
All manuscripts reporting experiments using animals must include a statement in the Methods section giving assurance that all animals received humane care in compliance with the 'Principles of Laboratory Animal Care' formulated by the National Society for Medical Research and the 'Guide for the Care and Use of Laboratory Animals' prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 86-23, revised 1996).
Authorship/Author Contributions
Each person designated as author should qualify for authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. The contributions to author section of the manuscript should concisely detail each author's role in the study, to include their study design, data analysis, writing of manuscript, acquisition of funding. This section should come after the Discussion and before the Acknowledgments and More details for such qualification can be found by accessing http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html.
Authors for whom English is not their native language are strongly encouraged to seek the aid of a professional English language medical editing service. JHLT endorses the use of Elsevier Author Services: https://webshop.elsevier.com/
Acknowledgments
Funding acknowledgments and any other notable acknowledgments (i.e., use of services to enhance writing of the manuscript) should be placed in a separate section, to come after Author Contributions and before Disclosures.
CONFLICT OF INTEREST DISCLOSURE AND MANAGEMENT FOR AUTHORS
Introduction
In order to ensure and protect the integrity of the JHLT, the ISHLT has developed these policies on COI as it applies to the JHLT, its Editor-in-Chief, Deputy Editors, Section Editors, Guest/Other Editors, and Editorial Board members/Reviewers, as well as authors of manuscripts submitted to JHLT for consideration for publication. This policy is based upon the foundational work of The International Committee of Medical Journal Editors (ICMJE), which updated its Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals in December 2019, see http://www.icmje.org/icmje-recommendations.pdf. Further guidance came from the Committee on Publication Ethics, COPE, see https://publicationethics.org/competinginterests and the World Association of Medical Editors, WAME, see http://wame.org/conflict-of-interest-in-peer-reviewed-medical-journals. The JHLT COI principles below are embodied within the ICMJE Recommendations and reflect accepted COI practice for major journals.
Conflict of Interest
An actual or potential conflict of interest occurs when a competing interest (financial, competitive, or otherwise) does or may influence (intentionally or not) the assessment of the validity of the interpretation of data and results. It is recognized that many authors and members of editorial boards have competing interests, and it is often not clear to journal readers, researchers, and editorial board members when a competing interest affects decision-making. Disclosure of all actual or potential conflicts allows all parties to make informed judgments.
The following competing interests or relationships must be disclosed by all Authors, Reviewers, and Editors ("covered individuals"), including when such interests/relationships are those of a spouse, child, or any other individual with whom the covered individual shares income or assets:
Employment: Employment with an entity having an investment, licensing, or other commercial interest in the subject matter under consideration must be disclosed.
Leadership Position: Service as an officer or director for an entity having an investment, licensing, or other commercial interest in the subject matter under consideration must be disclosed.
Consultant/Advisory Role/Expert Testimony: Arrangements with an entity having an investment, licensing, or other commercial interest in the subject matter under consideration must be disclosed if payments are made within the past 24 months or anticipated to be paid in the current or upcoming 12 months, regardless of whether payment was made to the individual or his/her institution. Payments totaling less than $500 per incident are excluded from disclosure requirements.
Stock Ownership/Patents: Any ownership interest including stock, options, and warrants (except when invested in a publicly traded fund not controlled by the covered individual) in any publicly traded or privately held company, and/or any patents generating income in the past 24 months or anticipated to generate income in the current or upcoming 12 months must be disclosed if the company is an entity having an investment, licensing, or other commercial interest in the subject matter under consideration.
Honoraria: Disclosure of honoraria for presentations or other services is required if payments are made by an entity having an investment, licensing, or other commercial interest in the subject matter under consideration and are paid within the past 24 months or anticipated to be paid in the current or upcoming 12 months, regardless of whether payment was made to the individual or his/her institution. Payments totaling less than $500 per incident are excluded from disclosure requirements. Payments totaling less than $500 per incident are excluded from disclosure requirements.
Research Funding: All payments (including in-kind payments) associated with the conduct of research in which the disclosing individual is participating/has participated must be disclosed if the payment is provided by or on behalf of a company having an investment, licensing, or other commercial interest in the subject matter under consideration, and is paid within the past 24 months or anticipated to be paid in the current or upcoming 12 months, regardless of whether payment was made to the individual or his/her institution.
Other Compensation: Trips, travel, gifts, or other in-kind payments, including those not directly related to specific research activities, must be disclosed if received from an entity having an investment, licensing, or other commercial interest in the subject matter under consideration and are paid within the past 24 months or are anticipated to be paid in the current or upcoming 12 months, regardless of whether payment was made to the individual or his/her institution, or a third party on the individual's behalf. Payments totaling less than $500 per incident are excluded from disclosure requirements.
Conflict of interest disclosure for authors
The ISHLT and the JHLT currently abide by the ICMJE Recommendations ("the Uniform Requirements") as they relate to authors. Accordingly:
All listed authors must complete and submit to JHLT at the time of manuscript submission the ICMJE's standardized disclosure form, which can be found at http://www.icmje.org/coi_disclosure.pdf. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure of all relationships described above.
Such disclosure must include actual or potential conflicts of interest related to all aspects of the manuscript. This includes any actual or potential competing interest related to the design and conduct of the study and interpretation of the study data.
In addition, each manuscript, regardless of its type, must include a financial conflict of interest disclosure statement. This statement should be included AFTER the Discussion Section and BEFORE the References in a separate section. This statement must include all funding sources or acknowledgements of contributions of any material nature pertinent to the manuscript and must describe ALL authors' relationships with companies or relevant entities that make products pertinent to the manuscript. The statement must specify the type of relationships (e.g., consulting, paid speaking, grant support, equity, patents) EACH author has with EACH company. The role(s) of any funding organization(s), if any, in the collection of data, its analysis and interpretation, and/or in the right to approve or disapprove publication of the finished manuscript must be described in this statement as well. This information is of serious concern to the Editorial Office and no manuscripts will move forward for processing if this statement is not provided as described herein.
Authors must completely spell out all grant funding agency abbreviations.
If an author has no conflicts to declare, he or she must indicate None.
Failure to include the disclosure statement at the time of manuscript submission will result in the Editorial Office returning the manuscript, which may be resubmitted provided the disclosure is included with the next submission. Allegations of inappropriate disclosure will be investigated.
Consequences of not disclosing COI
There are serious consequences for any author failing to disclose potential or actual conflicts of interest. These will be determined on a case-by-case basis and may include:
Ban from publishing in JHLT for from 1 year to indefinitely
Expression of concern published in JHLT
Retraction of article
Instigation of institutional inquiry into scientific misconduct
Report to Retraction Watch of misconduct
STYLE GUIDELINES
Manuscripts should be organized in the following order:
Title page, Abstract, Introduction, Materials and Methods, Results, Discussion, Author Contributions, Acknowledgments, Financial Disclosure Statement, Figures with Legends, References
Number all pages including figures, references and tables.
Title Page
The title page should include the following:
Authors and affiliations
Corresponding author contact information (see above for details)
Running Title
List of non-standard abbreviations
Word count
……
更多详情：
https://www.elsevier.com/journals/the-journal-of-heart-and-lung-transplantation/1053-2498/guide-for-authors
